KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Sales (2016 - 2025)

Historic Return on Sales for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to 0.1%.

  • Alnylam Pharmaceuticals' Return on Sales rose 2400.0% to 0.1% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.09%, marking a year-over-year increase of 2100.0%. This contributed to the annual value of 0.08% for FY2025, which is 2100.0% up from last year.
  • According to the latest figures from Q4 2025, Alnylam Pharmaceuticals' Return on Sales is 0.1%, which was up 2400.0% from 0.2% recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Return on Sales ranged from a high of 0.2% in Q3 2025 and a low of 1.54% during Q3 2022
  • Its 5-year average for Return on Sales is 0.55%, with a median of 0.58% in 2023.
  • In the last 5 years, Alnylam Pharmaceuticals' Return on Sales skyrocketed by 17300bps in 2023 and then tumbled by -4700bps in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Return on Sales stood at 1.0% in 2021, then soared by 38bps to 0.62% in 2022, then soared by 49bps to 0.31% in 2023, then surged by 55bps to 0.14% in 2024, then surged by 172bps to 0.1% in 2025.
  • Its last three reported values are 0.1% in Q4 2025, 0.2% for Q3 2025, and 0.09% during Q2 2025.